43 results on '"Dreger, Peter"'
Search Results
2. Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies.
- Author
-
Janssen, Maike, Leo, Albrecht, Wolf, Cornelia, Stenzinger, Miriam, Bartenschlager, Marie, Brandt, Juliane, Sauer, Sandra, Schmitt, Michael, Dreger, Peter, Schlenk, Richard F., Denkinger, Claudia M., and Müller‐Tidow, Carsten
- Subjects
COVID-19 treatment ,COVID-19 ,HEMATOLOGIC malignancies ,IMMUNOCOMPROMISED patients ,MEDIAN (Mathematics) - Abstract
Immunocompromised patients are at high risk to fail clearance of SARS‐CoV‐2. Prolonged COVID‐19 constitutes a health risk and a management problem as cancer treatments often have to be disrupted. As SARS‐CoV‐2 evolves, new variants of concern have emerged that evade available monoclonal antibodies. Moreover, antiviral therapy promotes SARS‐CoV‐2 escape mutations, particularly in immunocompromised patients. These patients frequently suffer from prolonged infection. No successful treatment has been established for persistent COVID‐19 infection. Here, we report on a series of 21 immunocompromised patients with COVID‐19—most of them hematologic malignancies—treated with plasma obtained from recently convalescent or vaccinated donors or a combination thereof. Repeated dosing of SARS‐CoV‐2‐antibody‐containing plasma could clear SARS‐CoV‐2 infection in 16 out of 21 immunocompromised patients even if COVID‐19‐specific treatments failed to induce sustained viral clearance or to improve clinical course of SARS‐CoV‐2 infection. Ten patients were major responders defined as an increase delta(d)Ct of > = 5 after the first administration of convalescent and/or vaccinated plasma (C/VP). On average, SARS‐CoV‐2 PCR Ct values increased from a median value of 22.55 (IQR = 19.10–24.25) to a median value of 29.57 (IQR = 27.55–34.63; p = <.0001) in the major response subgroup. Furthermore, when treated a second time with C/VP, even 4 out of 5 of the initial nonresponders showed an increase in Ct‐values from a median value of 23.13 (IQR = 17.75–28.05) to a median value of 32.79 (IQR = 31.75–33.75; p =.013). Our results suggest that C/VP could be a feasible treatment of COVID‐19 infection in patients with hematologic malignancies who did not respond to antiviral treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany.
- Author
-
Frietsch, Jochen J., Flossdorf, Sarah, Beck, James F., Kröger, Nicolaus, Fleischhauer, Katharina, Dreger, Peter, Schetelig, Johannes, Bornhäuser, Martin, Hochhaus, Andreas, and Hilgendorf, Inken
- Subjects
HEMATOPOIETIC stem cell transplantation ,YOUNG adults ,STEM cell transplantation ,ACHIEVED status ,OLDER patients - Abstract
Summary: Young adults (YA) represent a minority among recipients of allogeneic haematopoietic stem cell transplantation (HSCT). In order to describe the outcome of YA following HSCT in Germany, 9299 patients who were registered with the German Registry for Stem Cell Transplantation were included in this retrospective analysis of the years 1998–2019. The impact of the variables, such as patient age and sex, sex differences, stem cell source, donor type, conditioning, year of HSCT, the diagnosis, and the achieved remission status were tested in univariable and multivariable analysis for overall, event‐free and relapse‐free survival as well as for the cumulative incidences of non‐relapse and therapy‐related mortality. Altogether, the outcome of YA after HSCT improved over time and was determined by the underlying disease, the age at disease onset, stem cell source, and donor type. Patients were most likely to die from relapse, and survival of HSCT recipients after 10 years was reduced by more than half in comparison to the general population of YA. Deeper understanding of modifiable risk factors may be gained by studies comparing the outcome of YA post‐HSCT with that of children, adolescents and elderly patients. A deliberate and strong patient selection may further improve mortality rates. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Statin‐based endothelial prophylaxis and outcome after allogeneic stem cell transplantation.
- Author
-
Pabst, Caroline, Schreck, Nicholas, Benner, Axel, Hegenbart, Ute, Schönland, Stefan, Radujkovic, Aleksandar, Schmitt, Michael, Müller‐Tidow, Carsten, Orsatti, Laura, Dreger, Peter, and Luft, Thomas
- Subjects
STEM cell transplantation ,HEMATOPOIETIC stem cell transplantation ,ENDOTHELIUM diseases ,INDOLEAMINE 2,3-dioxygenase ,ADVERSE health care events ,ENZYME metabolism - Abstract
Background: Allogeneic haematopoietic stem cell transplantation (alloSCT) often remains the only curative therapy for hematologic malignancies. Although the management of transplant‐associated adverse events considerably improved over the last decades, nonrelapse mortality (NRM) remains a challenge, and endothelial dysfunction was identified as a major contributor to NRM. Methods: Statin‐based endothelial prophylaxis (SEP) has been implemented in the standard of care in our transplant centre to reduce NRM caused by endothelial injury. Here, we retrospectively analysed the impact of SEP on clinical outcome in a cohort of 347 alloSCT patients. Results: SEP (n = 209) was associated with significantly reduced NRM (hazard ratio 0.61, 95% CI 0.38–0.96) and better overall survival (OS) after acute graft‐versus‐host disease (HR 0.59, 95% CI 0.37–0.93). Subgroup analyses showed that the NRM benefit was mainly found in patients with an intermediate endothelial activation and stress index (EASIX), while relapse risk was not affected. On day 100 post‐alloSCT, patients receiving SEP had significantly higher levels of the rate‐limiting enzyme of tryptophan metabolism, indoleamine 2,3‐dioxygenase (IDO), higher kynurenine to tryptophan ratios as a proxy of IDO activity and tended to have lower levels of the endothelial injury marker ST2 (p =.055). No significant differences in interferon‐gamma or IL18 levels were observed. These biomarker signatures suggest that the beneficial effects of SEP might be mediated by both endothelial protection and immunomodulation. Conclusions: Together, these data suggest that SEP improves NRM and OS post‐alloSCT in particular in patients with intermediate endothelial risk and provide first mechanistic clues about its potential mode of action. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Drug‐microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL.
- Author
-
Bruch, Peter‐Martin, Giles, Holly AR, Kolb, Carolin, Herbst, Sophie A, Becirovic, Tina, Roider, Tobias, Lu, Junyan, Scheinost, Sebastian, Wagner, Lena, Huellein, Jennifer, Berest, Ivan, Kriegsmann, Mark, Kriegsmann, Katharina, Zgorzelski, Christiane, Dreger, Peter, Zaugg, Judith B, Müller‐Tidow, Carsten, Zenz, Thorsten, Huber, Wolfgang, and Dietrich, Sascha
- Subjects
CHRONIC lymphocytic leukemia ,CHRONIC leukemia ,LYMPHOCYTIC leukemia ,PROGNOSIS ,DRUG resistance ,FLUDARABINE - Abstract
The tumour microenvironment and genetic alterations collectively influence drug efficacy in cancer, but current evidence is limited and systematic analyses are lacking. Using chronic lymphocytic leukaemia (CLL) as a model disease, we investigated the influence of 17 microenvironmental stimuli on 12 drugs in 192 genetically characterised patient samples. Based on microenvironmental response, we identified four subgroups with distinct clinical outcomes beyond known prognostic markers. Response to multiple microenvironmental stimuli was amplified in trisomy 12 samples. Trisomy 12 was associated with a distinct epigenetic signature. Bromodomain inhibition reversed this epigenetic profile and could be used to target microenvironmental signalling in trisomy 12 CLL. We quantified the impact of microenvironmental stimuli on drug response and their dependence on genetic alterations, identifying interleukin 4 (IL4) and Toll‐like receptor (TLR) stimulation as the strongest actuators of drug resistance. IL4 and TLR signalling activity was increased in CLL‐infiltrated lymph nodes compared with healthy samples. High IL4 activity correlated with faster disease progression. The publicly available dataset can facilitate the investigation of cell‐extrinsic mechanisms of drug resistance and disease progression. Synopsis: Combined perturbation by microenvironmental stimuli and drugs of chronic lymphocytic leukaemia cells annotated for genetic alterations reveals distinct response patterns and molecular modulators. CLL samples fall into four subgroups with distinct progression dynamics based on their microenvironmental response.Trisomy 12 enhances the response to microenvironmental stimulation and has a distinct transcription factor activity profile which is inhibited by IBET‐762 treatment.Linear modelling reveals different types of drug ‐ stimuli interactions, the most common being drug resistance induced by microenvironmental stimulation.IL4 and TLR signalling is more active in CLL infiltrated lymph nodes, and higher IL4 signalling activity correlates with faster disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
- Author
-
Beelen, Dietrich W., Stelljes, Matthias, Reményi, Péter, Wagner‐Drouet, Eva‐Maria, Dreger, Peter, Bethge, Wolfgang, Ciceri, Fabio, Stölzel, Friedrich, Junghanß, Christian, Labussiere‐Wallet, Hélène, Schaefer‐Eckart, Kerstin, Grigoleit, Goetz U., Scheid, Christof, Patriarca, Francesca, Rambaldi, Alessandro, Niederwieser, Dietger, Hilgendorf, Inken, Russo, Domenico, Socié, Gérard, and Holler, Ernst
- Published
- 2022
- Full Text
- View/download PDF
7. Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation.
- Author
-
Mai, Elias K., Schmitt, Thomas, Radujkovic, Aleksandar, König, Laila, Goldschmidt, Hartmut, Ho, Anthony D., Luft, Thomas, Müller‐Tidow, Carsten, Dreger, Peter, Hegenbart, Ute, and Schönland, Stefan O.
- Subjects
STEM cell transplantation ,AUTOTRANSPLANTATION ,ACUTE diseases ,MULTIPLE myeloma ,HEMATOPOIETIC stem cell transplantation ,GRAFT versus host disease - Abstract
Finally, other potential treatment options to reduce relapse/progression post alloSCT include post-transplantation cyclophosphamide (ptCy). Keywords: myeloma therapy; stem cell transplantation; cytogenetics EN myeloma therapy stem cell transplantation cytogenetics 244 248 5 12/27/21 20220101 NES 220101 Treatment of patients with relapsed multiple myeloma (MM) after autologous stem cell transplantation (autoSCT) remains challenging. Consequently, a future goal in MM therapy is to combine modern treatment concepts and alloSCT in suitable patients to reduce disease burden and enhance disease control in patients with relapsed high-risk MM. Details on re-induction treatment and response rates prior to alloSCT, engraftment and post alloSCT response rates, maintenance therapy, donor lymphocyte infusions (DLI) and relapse therapies are shown in Table I. The median age at alloSCT was 50 (range 34-64) years. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
8. P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR‐T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA.
- Author
-
Gagelmann, Nico, Bishop, Michael, Dreger, Peter, Glass, Bertram, Ayuk, Francis, Bethge, Wolfgang, and Kröger, Nicolaus
- Published
- 2023
- Full Text
- View/download PDF
9. Allogeneic stem cell transplant in non-Hodgkin lymphomas: Still an indication?
- Author
-
Dreger, Peter
- Subjects
STEM cell transplantation ,HEMATOPOIETIC stem cell transplantation ,NON-Hodgkin's lymphoma ,LYMPHOMAS ,CANCER treatment ,LYMPHOMA treatment ,HOMOGRAFTS - Abstract
Allogeneic hematopoietic cell transplantation (alloHCT) used to play a defined role in the treatment of non-Hodgkin lymphoma (NHL). With the advent of modern targeted molecular therapies and immunotherapies, treatment standards at least for B-cell lymphoma have undergone significant changes, thereby questioning the traditional role of alloHCT in these diseases. This paper attempts to describe the current place and the perspectives of alloHCT in the rapidly evolving treatment landscape of NHL. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients.
- Author
-
Fan, Fuli, Yoo, Hyeon Joo, Stock, Sophia, Wang, Lei, Liu, Yibin, Schubert, Maria‐Luisa, Wang, Sanmei, Neuber, Brigitte, Hückelhoven‐Krauss, Angela, Gern, Ulrike, Schmitt, Anita, Müller‐Tidow, Carsten, Dreger, Peter, Schmitt, Michael, and Sellner, Leopold
- Subjects
CHRONIC lymphocytic leukemia ,CHIMERIC antigen receptors ,FLUDARABINE ,LYMPHOBLASTIC leukemia ,ACUTE leukemia ,PROTEIN-tyrosine kinases - Abstract
Chimeric antigen receptor T (CART) cells targeting CD19 have shown promising results in the treatment of chronic lymphocytic leukemia (CLL). However, efficacy seems to be inferior compared to diffuse large B‐cell lymphoma or acute lymphoblastic leukemia. Impaired T‐cell fitness of CLL patients may be involved in treatment failure. Less‐differentiated naïve‐like T cells play an important role in CART expansion and long‐term persistence in vivo. These cells are sparse in CLL patients. Therefore, optimization of CART cell production protocols enriching less differentiated T cell subsets may overcome treatment resistance. The B‐cell receptor inhibitor ibrutinib targeting Bruton's tyrosine kinase (BTK) is approved for the treatment of CLL. Besides BTK, ibrutinib additionally inhibits interleukin‐2‐inducible T‐cell kinase (ITK) which is involved in T‐cell differentiation. To evaluate the effect of ibrutinib on CART cell production, peripheral blood mononuclear cells from nine healthy donors and eight CLL patients were used to generate CART cells. T‐cell expansion and phenotype, expression of homing and exhaustion makers as well as functionality of CART cells were evaluated. CART cell generation in the presence of ibrutinib resulted in increased cell viability and expansion of CLL patient‐derived CART cells. Furthermore, ibrutinib enriched CART cells with less‐differentiated naïve‐like phenotype and decreased expression of exhaustion markers including PD‐1, TIM‐3 and LAG‐3. In addition, ibrutinib increased the cytokine release capacity of CLL patient‐derived CART cells. In summary, BTK/ITK inhibition with ibrutinib during CART cell culture can improve yield and function of CLL patient‐derived CART cell products. What's new? Chimeric antigen receptor T (CART) cells targeting CD19 have shown promising results in chronic lymphocytic leukemia (CLL). However, naïve‐like T cells play an important role in CART expansion and long‐term persistence in vivo, and these cells are sparse in CLL patients. Here, the authors show that BTK/ITK inhibition with Ibrutinib during CART cell generation may improve CLL patient‐derived CART cell products and enhance CART cell function. Supplementing CART cell production with ibrutinib increases CART cell yields and enriches CART cells with less‐differentiated phenotypes and lower expression of exhaustion markers, representing a potential avenue to improve the clinical outcome of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
- Author
-
Roider, Tobias, Wang, Xi, Hüttl, Katrin, Müller‐Tidow, Carsten, Klapper, Wolfram, Rosenwald, Andreas, Stewart, James Peter, Castro, David Gonzalez, Dreger, Peter, Hermine, Olivier, Kluin‐Nelemans, Hanneke C., Grabe, Niels, Dreyling, Martin, Pott, Christiane, Ott, German, Hoster, Eva, and Dietrich, Sascha
- Subjects
MANTLE cell lymphoma ,ACUTE myeloid leukemia ,CYTARABINE ,B cells ,ENZYME metabolism ,HIV status - Abstract
The sterile alpha motif and histidine‐aspartic domain‐containing protein 1 (SAMHD1) has been demonstrated to predict the response to high‐dose cytarabine consolidation treatment in acute myeloid leukemia patients. Here, we evaluated SAMHD1 as potential biomarker for the response to high‐dose cytarabine in mantle cell lymphoma (MCL) patients. We quantified SAMHD1 protein expression and determined the mutation status in patients of the MCL Younger and Elderly trials (n = 189), who had received high‐dose cytarabine‐ or fludarabine‐based polychemotherapy. Additionally, we quantified SAMHD1 expression in B cell lymphoma cell lines and exposed them to cytarabine, fludarabine, and clinically relevant combinations. Across both trials investigated, SAMHD1 mutations had a frequency of 7.1% (n = 13) and did not significantly affect the failure‐free survival (FFS, P =.47). In patients treated with high‐dose cytarabine‐ or fludarabine‐containing regimes, SAMHD1 expression was not significantly associated with FFS or complete remission rate. SAMHD1 expression in B cell lymphoma cell lines, however, inversely correlated with their in vitro response to cytarabine as single agent (R =.65, P =.0065). This correlation could be reversed by combining cytarabine with other chemotherapeutics, such as oxaliplatin and vincristine, similar to the treatment regime of the MCL Younger trial. We conclude that this might explain why we did not observe a significant association between SAMHD1 protein expression and the outcome of MCL patients upon cytarabine‐based treatment. What's new? While mantle cell lymphoma (MCL) treatment has improved, relapse and unfavorable outcome remain problematic. Here, to better predict therapeutic response in MCL, the authors assessed the biomarker potential of the nucleotide metabolism enzyme SAMHD1. Analyses of patients in the MCL Younger and Elderly trial show that neither SAMHD1 protein expression nor mutation status are associated with failure‐free survival or complete remission rate upon cytarabine‐based treatment in MCL patients. Drug perturbation assays in B cell lymphoma cell lines suggest that high SAMHD1 expression mediates cytarabine resistance as monotherapy but not when combined with other chemotherapeutics, similar to MCL treatment in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. B‐cell maturation antigen‐specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives.
- Author
-
Sellner, Leopold, Fan, Fuli, Giesen, Nicola, Schubert, Maria‐Luisa, Goldschmidt, Hartmut, Müller‐Tidow, Carsten, Dreger, Peter, Raab, Marc S., and Schmitt, Michael
- Subjects
CHIMERIC antigen receptors ,MULTIPLE myeloma ,SEVERE combined immunodeficiency ,INCURABLE diseases - Abstract
Despite major advances in the treatment of multiple myeloma (MM), it remains a largely incurable disease with long‐term control often dependent on continuous therapy. More effective, better tolerated treatments are therefore required to achieve durable remissions and to improve the quality of life of MM patients. Adoptive immunotherapy employing T cells expressing chimeric antigen receptors (CAR) is currently among the most promising treatment approaches in cancer. Within the target portfolio for MM immunotherapy, B‐cell maturation antigen (BCMA) is among the most widely studied target antigens. BCMA is consistently expressed on MM cells and, importantly, is not expressed in critical healthy tissue. For this reason, it is an ideal target for MM immunotherapy. Several clinical trials evaluating different BCMA‐targeting CAR constructs have been initiated and early results are very promising. However, in this rapidly developing clinical landscape, the ultimate role of BCMA‐specific CAR‐T cell therapy remains unclear. In this review, we will summarize currently available clinical data on BCMA‐directed CAR‐T cells and discuss potential future perspective for this promising treatment approach in MM. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP‐EBMT study.
- Author
-
Bazarbachi, Ali, Boumendil, Ariane, Finel, Hervé, Castagna, Luca, Dominietto, Alida, Blaise, Didier, Diez‐Martin, Jose L., Tischer, Johanna, Gülbas, Zafer, Wallet, Hélène L., Corral, Lucia L., Mohty, Mohamad, Koc, Yener, Yakoub‐Agha, Ibrahim, Schmid, Christoph, El Cheikh, Jean, Arat, Mutlu, Forcade, Edouard, Dreger, Peter, and Rocha, Vanderson
- Subjects
STEM cells ,BONE marrow cells ,STEM cell transplantation ,TRANSPLANTATION of organs, tissues, etc. ,GRAFT versus host disease - Abstract
Summary: Haploidentical stem cell transplantation (haploSCT) is becoming a major transplant modality for lymphoma. To assess the effects of donor characteristics, stem cell source and conditioning on outcomes, we identified 474 adults with Hodgkin (HL; 240), peripheral T‐cell (PTCL; 88), diffuse large B‐cell (77), mantle cell (40) or follicular lymphoma (FL; 29), who received haploSCT with post‐transplant cyclophosphamide. Median follow‐up of alive patients was 32 months. On multivariate analysis, acute graft‐versus‐host disease (GVHD) grade 2–4 was lower with offspring donors or bone marrow cells, whereas extensive chronic GVHD was higher in partial response at haploSCT or when using sisters, haploidentical donors beyond first degree, or female donors in male patients. Progression‐free survival (PFS) was better for FL, HL and PTCL, whereas overall survival (OS) was better for HL and PTCL. Complete remission at haploSCT improved PFS and OS whereas these were negatively affected by cytomegalovirus donor positive/recipient positive status. No other donor characteristics (age, gender, human leucocyte antigen mismatch, ABO incompatibility) affected PFS or OS except use of haploidentical donors beyond first degree, which negatively affected OS. PFS and OS are mostly influenced by disease status and lymphoma subtype, supporting the use of any first degree haploidentical family member as a donor. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Idelalisib for optimized CD19‐specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
- Author
-
Stock, Sophia, Übelhart, Rudolf, Schubert, Maria‐Luisa, Fan, Fuli, He, Bailin, Hoffmann, Jean‐Marc, Wang, Lei, Wang, Sanmei, Gong, Wenjie, Neuber, Brigitte, Hückelhoven‐Krauss, Angela, Gern, Ulrike, Christ, Christiane, Hexel, Monika, Schmitt, Anita, Schmidt, Patrick, Krauss, Jürgen, Jäger, Dirk, Müller‐Tidow, Carsten, and Dreger, Peter
- Subjects
CHRONIC lymphocytic leukemia ,CHIMERIC antigen receptors ,T cell receptors ,FLUDARABINE ,B cell receptors ,T cell differentiation ,BLOOD cells - Abstract
Despite encouraging results with chimeric antigen receptor T (CART) cells, outcome can still be improved by optimization of the CART cell generation process. The proportion of less‐differentiated T cells within the transfused product is linked to enhanced in vivo CART cell expansion and long‐term persistence. The clinically approved PI3Kδ inhibitor idelalisib is well established in the treatment of B cell malignancies. Besides B cell receptor pathway inhibition, idelalisib can modulate T cell differentiation and function. Here, detailed longitudinal analysis of idelalisib‐induced effects on T cell phenotype and function was performed during CART cell production. A third generation CD19.CAR.CD28.CD137zeta CAR vector system was used. CART cells were generated from peripheral blood mononuclear cells of healthy donors (HDs) and chronic lymphocytic leukemia (CLL) patients. Idelalisib‐based CART cell generation resulted in an enrichment of less‐differentiated naïve‐like T cells (CD45RA+CCR7+), decreased expression of the exhaustion markers PD‐1 and Tim‐3, as well as upregulation of the lymph node homing marker CD62L. Idelalisib increased transduction efficiency, but did not impair viability and cell expansion. Strikingly, CD4:CD8 ratios that were altered in CART cells from CLL patients were approximated to ratios in HDs by idelalisib. Furthermore, in vivo efficacy of idelalisib‐treated CART cells was validated in a xenograft mouse model. Intracellular TNF‐α and IFN‐γ production decreased in presence of idelalisib. This effect was reversible after resting CART cells without idelalisib. In summary, PI3Kδ inhibition with idelalisib can improve CART cell products, particularly when derived from CLL patients. Further studies with idelalisib‐based CART cell generation protocols are warranted. What's new? Despite encouraging results with anti‐CD19 chimeric antigen receptor T (CART) cell therapy for B cell malignancies, clinical outcome could still be improved by optimization of the CART cell generation process. Here, the authors show that ex vivo PI3Kδ inhibition by the B cell malignancy drug idelalisib during CART cell generation can increase the proportion of less‐differentiated T cells and lead to a less exhausted T cell phenotype. Idelalisib optimized the phenotype of CART cells derived from chronic lymphocytic leukemia (CLL) patients. This study thus provides important novel and potentially practice‐changing findings for CART cell generation and expansion, especially for CLL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. CD7 is expressed on a subset of normal CD34‐positive myeloid precursors.
- Author
-
Kriegsmann, Katharina, Löffler, Harald, Eckstein, Volker, Schulz, Renate, Kräker, Sandra, Braun, Ute, Luft, Thomas, Hegenbart, Ute, Schönland, Stefan, Dreger, Peter, Krämer, Alwin, Ho, Anthony D., Müller‐Tidow, Carsten, and Hundemer, Michael
- Subjects
TUMORS ,FLOW cytometry ,CHIMERISM ,STEM cell transplantation ,BONE marrow - Abstract
Abstract: Objective: To improve monitoring of myeloid neoplasms by flow cytometry‐based minimal residual disease (MRD) analysis, we analyzed the significance of leukemia‐associated immunophenotype (LAIP) markers in 44 patients. Methods: In a pilot study cohort, peripheral blood or bone marrow samples from 13 patients with myeloid neoplasms and one case of B lymphoblastic leukemia in complete hematologic remission after allogeneic bone marrow or stem cell transplantation were subjected to selection for leukemia‐specific phenotypes by fluorescence‐activated cell sorting using individual marker combinations, followed by PCR‐based chimerism analysis. Results: The feasibility of this method could be demonstrated, with selection being successful in 12 cases, including two cases where mixed chimerism was found exclusively in sorted cells. Interestingly, four specimens displayed full donor chimerism in cells expressing the presumably aberrant combination CD34
+ /CD7+ . Further analyses, including assessment of an independent cohort of 25 patients not affected by neoplastic bone marrow infiltration, revealed that normal myeloid precursors usually include a population coexpressing CD34, CD13, CD33, and CD7. Conclusion: We conclude that the combination CD34+ /CD7+ might not be suitable as an LAIP for MRD diagnostics and that a subset of normal myeloid precursors in the bone marrow expresses CD7. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
16. Chimeric antigen receptor transduced T cells: Tuning up for the next generation.
- Author
-
Schubert, Maria‐Luisa, Hoffmann, Jean‐Marc, Dreger, Peter, Müller‐Tidow, Carsten, and Schmitt, Michael
- Abstract
Chimeric antigen receptor (CAR) T cell therapy has recently achieved impressive clinical outcome in patients with CD19‐positive hematologic malignancies. Extrapolation of CAR T cell treatment to solid tumors, however, has not yet yielded similar results. This might be due to intrinsic causes, e.g. insufficient CAR T cell activation or CAR toxicity as well as extrinsic factors displaying an unfavorable tumor environment for CAR T cells by raising physical and chemical barriers. In this review, we discuss the advantages as well as major obstacles of CAR T cell therapy, particularly in the context of solid tumors, and focus on efforts and novel strategies in CAR T cell development. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
- Author
-
Sureda, Anna, Zhang, Mei‐Jie, Dreger, Peter, Carreras, Jeanette, Fenske, Timothy, Finel, Herve, Schouten, Harry, Montoto, Silvia, Robinson, Stephen, Smith, Sonali M., Boumedil, Ariane, Hamadani, Mehdi, Pasquini, Marcelo C., and Zhang, Mei-Jie
- Subjects
GRAFT versus host disease ,STEM cell transplantation ,LYMPHOMAS ,PROGNOSIS ,THERAPEUTICS - Abstract
Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only potentially curative treatment option for relapsed follicular lymphoma (FL), yet questions remain about the optimal timing. This study analyzed long-term outcomes and associated factors among recipients of allo-HCT with FL.Methods: Patients with relapsed FL who underwent allo-HCT from 2001 to 2011 with a human leukocyte antigen (HLA)-matched donor were included. Outcome analyses for overall survival (OS), progression-free survival (PFS), transplant-related mortality (TRM), and disease relapse/progression were calculated. A multivariate analysis was performed to determine factors associated with outcomes, and a prognostic score for treatment failure was developed in a subset analysis of patients.Results: In all, 1567 patients with relapsed FL were included; the median follow-up was 55 months. The 5-year probabilities of OS and PFS were 61% and 52%, respectively. The 5-year cumulative incidences of disease progression/relapse and TRM were 29% and 19%, respectively. Chemoresistant disease, older age, heavy pretreatment, poor performance status (PS), and myeloablative protocols were predictors for worse survival. The prognostic score, using age, lines of prior therapy, disease status, and PS, stratified patients into 3 groups-low, intermediate, and high risk-with 5-year PFS rates of 68%, 53%, and 46%, respectively, and 5-year OS rates of 80%, 62%, and 50%, respectively.Conclusions: Allo-HCT should be considered for patients with relapsed FL and available HLA-matched donors. Outcomes are better in earlier phases of the disease, and reduced-intensity conditioning should be preferred. The prognostic score presented here can assist in counseling patients and determining the time to proceed to transplantation. Cancer 2018;124:1733-42. © 2018 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
18. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
- Author
-
Bazarbachi, Ali, Boumendil, Ariane, Finel, Hervé, Mohty, Mohamad, Castagna, Luca, Peggs, Karl S., Blaise, Didier, Afanasyev, Boris, Diez‐Martin, José L., Sierra, Jorge, Bloor, Adrian, Martinez, Carmen, Robinson, Stephen, Malladi, Ram, El‐Cheikh, Jean, Corradini, Paolo, Montoto, Silvia, Dreger, Peter, and Sureda, Anna
- Subjects
ANTIBODY-drug conjugates ,IMMUNOPHARMACOLOGY ,STEM cell transplantation ,HODGKIN'S disease ,PROGRESSION-free survival - Abstract
Summary: Brentuximab vedotin (BV) is an anti‐CD30 antibody‐drug conjugate. Preliminary data suggest that BV might improve outcomes after allogeneic stem cell transplantation (SCT) for Hodgkin lymphoma (HL) when used as pre‐transplant salvage therapy. Between 2010 and 2014, 428 adult patients underwent an allogeneic SCT for classical HL at participating centres of the European Society for Blood and Marrow Transplantation. We compared the outcomes of 210 patients who received BV prior to allogeneic SCT with that of 218 patients who did not receive BV. The median follow‐up for survivors was 41 months. Patients in the BV group were more heavily pre‐treated (median pre‐allograft treatment lines: 4 vs. 3). The two groups were comparable in terms of disease status, performance status, comorbidities, prior autologous SCT, type of donor, conditioning and
in vivo T cell depletion. In multivariate analysis, pre‐allograft BV had no impact on acute graft‐versus‐host disease (GVHD), non‐relapse mortality, cumulative incidence of relapse, progression‐free survival or overall survival (OS), but significantly reduced the risk of chronic GVHD (hazard ratio = 0·64; 95% confidence interval = 0·45–0·92;P < 0·02). Older age, poor performance status, use of pre‐transplant radiotherapy and active disease at SCT adversely affected OS. Patients allografted for HL after prior exposure to BV do not have a superior outcome after allogeneic SCT except for a lower risk of chronic GVHD. However, BV may improve the outlook of allogeneic SCT by helping otherwise refractory patients to achieve a more favourable disease status, facilitating allotransplant success. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
19. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
- Author
-
Akhtar, Saad, Montoto, Silvia, Boumendil, Ariane, Finel, Herve, Masszi, Tamas, Jindra, Pavel, Nemet, Damir, Fuhrmann, Stephan, Beguin, Yves, Castagna, Luca, Ferrara, Felicetto, Capria, Saveria, Malladi, Ram, Moraleda, Jose Maria, Bloor, Adrian, Ghesquières, Hervé, Meissner, Julia, Sureda, Anna, and Dreger, Peter
- Published
- 2018
- Full Text
- View/download PDF
20. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial.
- Author
-
Scheffold, Annika, Jebaraj, Billy Michael Chelliah, Jaramillo, Sonia, Tausch, Eugen, Steinbrecher, Daniela, Hahn, Michael, Böttcher, Sebastian, Ritgen, Matthias, Bunjes, Donald, Zeis, Matthias, Stadler, Michael, Uharek, Lutz, Scheid, Christoph, Hegenbart, Ute, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, Döhner, Hartmut, Dreger, Peter, and Stilgenbauer, Stephan
- Subjects
LYMPHOCYTIC leukemia ,STEM cell transplantation ,TELOMERES ,STEM cell treatment ,CHROMOSOMES ,LEUKEMIA treatment ,THERAPEUTICS - Abstract
The article reports on a study which investigated the impact of telomere length on the outcome of allogeneic stem cell transplantation (SCT) for patients with poor risk chronic lymphocytic leukaemia (CLL) based on the German CLL3X trial which included 100 patients. Topics covered include association of telomere length with clinical characteristics, and analysis of telomere length using quantitative polymerase chain reaction.
- Published
- 2017
- Full Text
- View/download PDF
21. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas.
- Author
-
Gorkom, Gwendolyn, Finel, Herve, Giebel, Sebastian, Pohlreich, David, Shimoni, Avichai, Ringhoffer, Mark, Sucak, Gülsan, Schaap, Nicolaas, Dreger, Peter, Sureda, Anna, and Schouten, Harry C.
- Abstract
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) to rescue hematopoiesis is considered standard care for patients with a relapsed chemosensitive lymphoma, but diagnosis of lymphoma has been a risk factor for poor mobilization in several studies. The aim of this prospective noninterventional clinical audit was to review the mobilization strategies used by EBMT centers in relapsed lymphoma and to evaluate their efficacy. Between 2010 and 2014, 275 patients with relapsed lymphoma from 30 EBMT centers were prospectively registered. Almost all patients were mobilized with chemotherapy plus G-CSF (96%), but there was a large variation in chemotherapy schedules. Thirty (11%) of them were poor mobilizers (<2 × 10
6 CD 34+ cells/kg body weight) at the first mobilization. Poor mobilization was not associated with gender, age, bone marrow involvement at diagnosis, primary diagnosis, number of previous chemotherapy lines, previous radiotherapy or mobilization with G-CSF alone. The use of high dose cyclophosphamide alone was associated with mobilization failure ( P = 0.0006), whereas the use of a platinum-containing regimen was associated with a good mobilization outcome ( P = 0.013). Because failure rate is low, we can conclude from this study that PBSC mobilization failure in relapsed lymphomas is not an important problem in the EBMT centers. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
22. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation ( EBMT).
- Author
-
Schetelig, Johannes, Wreede, Liesbeth C., Andersen, Niels S., Moreno, Carol, Gelder, Michel, Vitek, Antonin, Karas, Michal, Michallet, Mauricette, Machaczka, Maciej, Gramatzki, Martin, Beelen, Dietrich, Finke, Jürgen, Delgado, Julio, Volin, Liisa, Passweg, Jakob, Dreger, Peter, Schaap, Nicolaas, Wagner, Eva, Henseler, Anja, and Biezen, Anja
- Subjects
HOMOGRAFTS ,CHRONIC lymphocytic leukemia ,STEM cell transplantation ,RETROSPECTIVE studies ,PROGRESSION-free survival ,CANCER risk factors - Abstract
The best approach for allogeneic haematopoietic stem cell transplantations (allo HCT) in patients with chronic lymphocytic leukaemia ( CLL) is unknown. We therefore analysed the impact of procedure- and centre-related factors on 5-year event-free survival ( EFS) in a large retrospective study. Data of 684 CLL patients who received a first allo HCT between 2000 and 2011 were analysed by multivariable Cox proportional hazards models with a frailty component to investigate unexplained centre heterogeneity. Five-year EFS of the whole cohort was 37% (95% confidence interval [ CI], 34-42%). Larger numbers of CLL allo HCTs (hazard ratio [ HR] 0·96, P = 0·002), certification of quality management ( HR 0·7, P = 0·045) and a higher gross national income per capita ( HR 0·4, P = 0·04) improved EFS. In vivo T-cell depletion ( TCD) with alemtuzumab compared to no TCD ( HR 1·5, P = 0·03), and a female donor compared to a male donor for a male patient ( HR 1·4, P = 0·02) had a negative impact on EFS, but not non-myeloablative versus more intensive conditioning. After correcting for patient-, procedure- and centre-characteristics, significant variation in centre outcomes persisted. In conclusion, further research on the impact of centre and procedural characteristics is warranted. Non-myeloablative conditioning appears to be the preferable approach for patients with CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
23. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
- Author
-
Radujkovic, Aleksandar, Dietrich, Sascha, Andrulis, Mindaugas, Benner, Axel, Longerich, Thomas, Pellagatti, Andrea, Nanda, Kriti, Giese, Thomas, Germing, Ulrich, Baldus, Stefan, Boultwood, Jacqueline, Ho, Anthony D., Dreger, Peter, and Luft, Thomas
- Abstract
We tested the hypothesis that proliferative activity of hematopoietic stem cells has impact on survival in newly diagnosed patients with myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (AML). RNA expression profiles of CD34
+ cells were analyzed in 125 MDS patients and compared to healthy controls. Prognostic impact on overall survival (OS) of mRNA proliferation signatures established for solid tumor cells was analyzed retrospectively. For validation on the protein level, immunofluorescence and immunohistochemistry analyses in bone marrow (BM) biopsies were performed, and an independent cohort of 223 MDS and secondary AML patients was investigated. Lower proliferative activity correlated with the expression of cyclin-dependent kinase inhibitor 1C ( CDKN1C) and with shorter OS ( p < 0.001). In multivariable analysis, higher CDKN1C expression was associated with worse OS ( p = 0.02). On the BM level, a total of 84 (38%) patients showed CDKN1C protein expression before start of treatment. Patient, disease and treatment characteristics did not differ between CDKN1C-positive and -negative patients. Positive CDKN1C BM status was associated with shorter OS in multivariable analysis (HR 1.54, p = 0.04). There was an interaction between CDKN1C BM status and subsequent treatment with negative impact on OS being most pronounced in patients receiving conventional cytotoxic chemotherapy ( n = 83, 2-year OS 30% versus 58%, p = 0.002). In conclusion, low-proliferative phenotype and CDKN1C expression were associated with shorter OS. CDKN1C protein expression in the BM of newly diagnosed, treatment-naïve MDS and secondary AML patients was identified as a prognostic factor for poor survival in patients treated with antiproliferative chemotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
24. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.
- Author
-
Witzens‐Harig, Mathias, Benner, Axel, McClanahan, Fabienne, Klemmer, Jennifer, Brandt, Julia, Brants, Elke, Rieger, Michael, Meissner, Julia, Hensel, Manfred, Neben, Kai, Dreger, Peter, Lengfelder, Eva, Schmidt‐Wolf, Ingo, Krämer, Alwin, and Ho, Anthony D.
- Subjects
RITUXIMAB ,B cell lymphoma ,GENDER differences (Psychology) ,LYMPHOMA diagnosis ,DISEASE relapse ,LYMPHOMA treatment ,CLINICAL trials ,TUMOR treatment - Abstract
In the multicentre prospective randomized HD2002 trial, rituximab maintenance therapy (375 mg/m² every 3 months for 2 years) versus observation was evaluated for CD20
+ B-cell lymphoma. Out of 321 patients [161 randomized to the treatment group (TG), 160 to the observation group (OG)], 295 data sets were evaluable for statistical analysis. Estimated 5-year relapse-free survival (RFS) was 81% in the TG and 70% in the OG (logrank test, P = 0.047). In the diffuse large B-cell lymphoma (DLBCL) subgroup (n = 152), 5-year RFS was excellent, at 87% in the TG and 84% in the OG (logrank test, P = 0.35). Of note, only in male patients of the DLBCL subgroup was RFS significantly superior in the TG in comparison to the OG (5-year RFS: 88% vs. 74%; logrank test, P = 0.05). Cox regression analysis showed a significant interaction between treatment and gender regarding overall survival (OS) (P = 0.006) and RFS (P = 0.02), with a lower hazard in females than males in the OG [OS: hazard ratio (HR) (female:male) = 0.11; 95% confidence interval (CI) = 0.00-1.03; RFS: HR (female:male) = 0.27; 95% CI = 0.05-0.97], and no significant differences between males and females in the TG. We conclude that Rituximab maintenance therapy improves survival in male patients with DLBCL. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
25. Effects of physical exercise on survival after allogeneic stem cell transplantation.
- Author
-
Wiskemann, Joachim, Kleindienst, Nikolaus, Kuehl, Rea, Dreger, Peter, Schwerdtfeger, Rainer, and Bohus, Martin
- Abstract
Observational studies have suggested that physical activity may be associated with improved survival after cancer treatment. However, data from controlled clinical trials are required. We analyzed survival data of 103 patients from a previously published randomized controlled trial in allogeneic stem cell transplant patients who were randomized to either an exercise intervention (EX) or to a social contact control group. EX patients trained prior to hospital admission, during inpatient treatment, and for 6-8 weeks after discharge. Survival analyses were used to compare both total mortality (TM) and non-relapse mortality (NRM) after discharge and transplantation during an observation period of 2 years after transplantation. Analyses were corroborated with Cox and Fine & Gray regression models adjusting for potential confounders. After discharge, EX patients had a significantly lower TM rate than controls (12.0 vs. 28.3%, p = 0.030) and a numerically lower NRM rate (4.0 vs. 13.5%, p = 0.086). When the inpatient period was included, absolute risk reductions were similar but not significantly different (TM: 34.0 vs. 50.9%, p = 0.112; NRM: 26.0 vs. 36.5%, p = 0.293). The number needed to treat (NNT) to prevent one death with EX was about 6. Furthermore, regression analyses revealed that baseline fitness was protective against mortality. The data suggest that exercise might improve survival in patients undergoing allo-HCT. However, the results should be interpreted with caution as the study was not designed to detect differences in survival rates, and as no stratification on relevant prognostic factors was carried out. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
26. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts - a retrospective single-center experience.
- Author
-
Radujkovic, Aleksandar, Dietrich, Sascha, Bochtler, Tilmann, Krämer, Alwin, Schöning, Tilman, Ho, Anthony D., Dreger, Peter, and Luft, Thomas
- Subjects
ACUTE myeloid leukemia ,AZACITIDINE ,CYTARABINE ,BONE marrow ,FEBRILE neutropenia ,MULTIVARIATE analysis ,PATIENTS ,THERAPEUTICS - Abstract
We retrospectively analyzed and compared the efficacy and toxicity of azacitidine ( AZA) and low-dose cytarabine ( LD- Ara- C) in 65 palliative patients with acute myeloid leukemia ( AML) showing high bone marrow blast counts (≥30%) before start of treatment. Twenty-seven and 38 patients received AZA and LD- Ara- C, respectively. The median patient age was 71 yr. Patient and disease characteristics did not differ between the treatment groups, except for BM blast counts, and peripheral leukocyte and blast counts which were significantly higher in the LD- Ara- C group. AZA and LD- Ara- C were first-line treatment in 12 (44%) and 17 patients (45%), respectively. Response and hematologic improvement rates were low and similar in both treatment groups. In both treatment groups, most common non-hematologic toxicities included febrile neutropenia, pneumonia, and bleedings without significant differences regarding frequencies. Estimated 1-yr survival rates were 15% (95% CI 8-22) and 13% (95% CI 7-19) in the AZA and LD- Ara- C groups, respectively, without statistically significant difference. In multivariate analysis ( n = 65), previous treatment ( HR 2.27, 95% CI 1.00-5.22, P = 0.05) and adverse cytogenetics ( HR 2.50, 95% CI 1.20-5.22, P = 0.02) were independent predictors of poor survival. In our center and within the limitations of a retrospective study, both treatment regimens showed similar but limited efficacy in palliative patients with AML and high BM blast counts. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
- Author
-
Kutsch, Nadine, Pallasch, Christian, Tausch, Eugen, Böhme, Volkmar, Ritgen, Matthias, Liersch, Rüdiger, Wacker, Alexander, Jacobs, Georg, Trappe, Ralf Ulrich, Dreger, Peter, Fischer, Kirsten, Fink, Anna‐Maria, Stilgenbauer, Stephan, Zhai, Shuyan, Li, Biao, Jürgensmeier, Juliane M., Rajakumaraswamy, Nishanthan, Bhargava, Pankaj, Hallek, Michael, and Eichhorst, Barbara F.
- Published
- 2022
- Full Text
- View/download PDF
28. Imatinib-supplemented myeloablative total-body irradiation/cyclophosphamide conditioning prior to allogeneic stem cell transplantation as consolidation treatment in patients with blast crisis of chronic myeloid leukemia.
- Author
-
Radujkovic, Aleksandar, Dreger, Peter, Hegenbart, Ute, Buss, Eike C., Luft, Thomas, Ho, Anthony D., Fruehauf, Stefan, and Topaly, Julian
- Subjects
- *
IMATINIB , *CHRONIC myeloid leukemia , *STEM cell transplantation , *PATIENTS - Abstract
A letter to the editor is presented which discusses the prospective studies on the effect of pretransplant imatinib in patients with blast crisis of chronic myeloid leukemia (BC-CML) after myeloablative allogeneic stem cell transplantation (allo-SCT).
- Published
- 2014
- Full Text
- View/download PDF
29. Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study.
- Author
-
Wreede, Liesbeth C., Watson, Maggie, Os, Marleen, Milligan, Donald, Gelder, Michel, Michallet, Mauricette, Dreger, Peter, Dearden, Claire E., Homewood, Janis, Dupuis, Jehan, Leporrier, Michel, Karas, Michal, Corront, Bernadette, Baerlocher, Gabriela M., Herr, Wolfgang, Choquet, Sylvain, Niederwieser, Dietger W., Sutton, Laurent, Kröger, Nicolaus, and Witte, Theo M.
- Published
- 2014
- Full Text
- View/download PDF
30. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia.
- Author
-
Jethwa, Alexander, Hüllein, Jennifer, Stolz, Tatjana, Blume, Carolin, Sellner, Leopold, Jauch, Anna, Sill, Martin, Kater, Arnon P., te Raa, G. Doreen, Geisler, Christian, Oers, Marinus, Dietrich, Sascha, Dreger, Peter, Ho, Anthony D., Paruzynski, Anna, Schmidt, Manfred, Kalle, Christof, Glimm, Hanno, and Zenz, Thorsten
- Subjects
NUCLEOTIDE sequence ,CHRONIC lymphocytic leukemia treatment ,HETEROGENEITY ,CANCER genetics ,CANCER genes - Abstract
Recurrent gene mutations contribute to the pathogenesis of chronic lymphocytic leukaemia (CLL). We developed a next-generation sequencing (NGS) platform to determine the genetic profile, intratumoural heterogeneity, and clonal structure of two independent CLL cohorts. TP53, SF3B1, and NOTCH1 were most frequently mutated (16-3%, 16-9%, 10-7%). We found evidence for subclonal mutations in 67-5% of CLL cases with mutations of cancer consensus genes. We observed selection of subclones and found initial evidence for convergent mutations in CLL. Our data suggest that assessment of (sub)clonal structure may need to be integrated into analysis of the mutational profile in CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
31. Comments on "Cost of decentralized CAR T cell production in an academic non‐profit setting".
- Author
-
Schmitt, Michael, Schmitt, Anita, Thalheimer, Markus, Dreger, Peter, and Müller‐Tidow, Carsten
- Subjects
T cells ,DRUG registration ,CHIMERIC antigen receptors - Abstract
Keywords: CAR T cells; cell therapy; costs; gene therapy; Immunotherapy EN CAR T cells cell therapy costs gene therapy Immunotherapy 514 515 2 11/27/20 20210115 NES 210115 We would like to comment on the article "Cost of decentralized CAR T cell production in an academic non-profit setting" by Ran et al1 published in your prestigious journal on June 14, 2020. Accordingly, is it possible that the authors simply calculated the costs for a research product and then added a gross estimate of regulatory costs? CAR T cells, cell therapy, costs, gene therapy, Immunotherapy. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
32. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma.
- Author
-
Dietrich, Sascha, Tielesch, Blanca, Rieger, Michael, Nickelsen, Maike, Pott, Christiane, Witzens-Harig, Mathias, Kneba, Michael, Schmitz, Norbert, Ho, Antony D., and Dreger, Peter
- Subjects
STEM cell transplantation ,CELL transplantation ,LYMPHOMAS ,CANCER relapse ,CANCER patients - Abstract
BACKGROUND: Autologous stem cell transplantation (autoSCT) has improved the outcome of patients with mantle cell lymphoma (MCL) considerably. However, little is known about the patterns and outcome of MCL recurrence after autoSCT. METHODS: The authors conducted a retrospective study of 118 patients with MCL who underwent autoSCT from August 1992 to August 2008 at 3 different referral centers in Germany. RESULTS: Fifty-two relapses occurred for a cumulative incidence of 46% after 5 years. Only 3 patients relapsed after 5 years (at 90 months, 91 months, and 171 months) after undergoing autoSCT. A Cox regression analysis of the incidence of relapse identified not receiving rituximab before autoSCT and undergoing salvage autoSCT as predictive factors for relapse, whereas cytosine arabinoside intensification; a total body irradiation-based, high-dose regimen; patient age; and year of transplantation had no influence. The median overall survival (OS) after relapse was 23 months. Twenty patients (39%) underwent allogeneic stem cell transplantation (alloSCT) for relapse, and 11 of those patients remained in ongoing complete remission at the time of the current report. It is noteworthy that there were 4 long-term survivors who lived for >5 years after relapse even without undergoing alloSCT. A Cox regression analysis of OS after relapse revealed that the response duration after autoSCT was an adverse predictor of OS, whereas alloSCT was associated with a significantly longer OS after relapse. CONCLUSIONS: The current results indicated that autoSCT was capable of inducing long-term remission up to 16 years after treatment, but the outcome of patients with MCL who relapsed after autoSCT was poor, especially if their response duration after autoSCT was short. However, for a subset of patients with relapsed MCL, alloSCT may offer the possibility of durable survival, and individual patients can enjoy long-term survival after relapse even without undergoing alloSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
33. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
- Author
-
Pott, Christiane, Schrader, Carsten, Brüggemann, Monika, Ritgen, Matthias, Harder, Lana, Raff, Thorsten, Tiemann, Markus, Dreger, Peter, and Kneba, Michael
- Subjects
BLASTOIDEA ,BONE marrow ,PHARMACOLOGY ,IMMUNOHISTOCHEMISTRY ,HISTOPATHOLOGY ,STEM cells - Abstract
Pott C, Schrader C, Brüggemann M, Ritgen M, Harder L, Raff T, Tiemann M, Dreger P, Kneba M. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.Eur J Haematol 2005: 74: 353–358.© Blackwell Munksgaard 2005.Objectives: Classical mantle cell lymphoma (MCL) and its blastoid variant (MCL-BV) are characterized by an extremely poor prognosis. Long-time survivors are rare, only very few patients with an overall survival over 10 years have been reported. We present a case of a 41-year-old male with a 12 yr history of MCL stage I to show, that very late relapses in MCL are possible and may present as a transformation into an aggressive blastoid variant and to illustrate the value of quantitative minimal residual disease (MRD) monitoring for treatment guidance.Methods: Diagnostic lymph node and bone marrow samples were investigated by immunohistochemistry. Clonality analysis was performed by immunoglobulin heavy chain gene(IGVH)and t(11;14) PCR. The MRD assessment was done by real-time quantitative PCR (RQ-PCR) on available follow-up samples.Results: By histologic review and sequencing of the clonalIGVHand t(11;14) PCR products we demonstrated a common clonal origin of the leucemic MCL-BV and the classical MCL diagnosed 12 yr earlier. Quantitative MRD assessment revealed significant MRD levels after intensive conventional chemotherapy including Rituximab. Therefore, treatment was early intensified by myeloablative radio-chemotherapy and allogeneic peripheral stem cell transplantation from an unrelated HLA-identical donor. This did not translate into a sustained remission as reflected by persisting MRD levels after transplantation and the patient died from rapid progressive disease 3.5 months after transplant.Conclusion: This report presents a rare case of long-term survivor of MCL with a progression of the original MCL cell clone to MCL-BV and demonstrates the clinical value of quantitative MRD assessment for optimized therapeutic management. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
34. Epstein–Barr virus‐associatedpost‐transplant lymphoproliferative disease after bone marrow transplantation mimicking graft‐versus‐host disease.
- Author
-
Claviez, Alexander, Tiemann, Markus, Wagner, Hans‐joachim, Dreger, Peter, and Suttorp, Meinolf
- Subjects
LYMPHOPROLIFERATIVE disorders ,BONE marrow transplant complications ,GRAFT versus host disease ,EPSTEIN-Barr virus ,HLA histocompatibility antigens - Abstract
Abstract: In contrast to solid organ transplantation (Tx), the incidence of post‐transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell Tx (HSCT) is generally low. This risk, however, is significantly elevated in patients receiving human leukocyte antigen (HLA) mis‐matched or T‐cell‐depleted grafts, or after treatment for severe graft‐versus‐host disease (GvHD). An 18‐yr‐old patient with positive Epstein–Barr virus (EBV) serology received a fully matched, unmanipulated bone marrow graft from an unrelated EBV‐positive donor for treatment of acute myeloid leukemia (AML) in second complete remission. GvHD prophylaxis was performed with cyclosporin A (CsA) and a short course of methotrexate. Four months after Tx, the patient developed ulcerative tonsillitis that was unresponsive to antibiotic treatment. Diarrhea appearing simultaneously was interpreted as gastrointestinal GvHD and steroids were added to CsA. A few days later the patient was admitted to hospital because of generalized seizure and pneumonia. Despite reduction of immunosuppression, intensification of anti‐viral treatment, and subsequent mechanical ventilation, the patient died of acute respiratory distress 6 days later. Autopsy demonstrated disseminated EBV‐induced, multi‐nodular lymphoma infiltration of the entire colon but no signs of GvHD. Moreover, both lungs, paratracheal lymph nodes, kidneys, thyroid gland, and liver were infiltrated with large B‐cell non‐Hodgkin’s lymphomas. This case underlines the rapid and aggressive course of EBV‐induced disseminated PTLD after HSCT, initially mimicking intestinal GvHD because of massive colonic lymphoma infiltration. Tissue biopsies should be performed early for establishing correct diagnosis, thus enabling specific therapy, e.g. infusion of donor leukocytes with cytotoxic T‐lymphocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
35. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemia.
- Author
-
Dreger, Peter, Glass, Bertram, Kuse, Rolf, Sonnen, Ruth, von Neuhoff, Nils, Bolouri, Human, Kneba, Michael, and Schmitz, Norbert
- Subjects
- *
LEGG-Calve-Perthes disease , *LYMPHOPROLIFERATIVE disorders , *STEM cell transplantation , *ELECTROPHORESIS , *THERAPEUTICS - Abstract
Waldenström's macroglobulinaemia (WM) is an incurable lymphoproliferative disorder. The purpose of this study was to investigate the role of autologous peripheral blood stem cell transplantation (ASCT) for the treatment of WM. Seven patients (untreated or after first-line therapy) with symptomatic WM underwent two or three cycles of Dexa-BEAM chemotherapy + G-CSF with stem cell harvesting and proceeded to total body irradiation and high-dose cyclophosphamide followed by reinfusion of ex-vivo B-cell-depleted stem cells. Engraftment was prompt, and procedure-related deaths did not occur. A strong reduction or normalization of BM infiltration and serum IgM levels occurred in all evaluable patients, but immunofixation electrophoresis revealed persistent paraproteinaemia in five of them. With 3–30 months of follow-up, all patients are alive without clinical or serological signs of disease progression. This pilot trial shows for the first time that high-dose radiochemotherapy with purged stem cells is effective and may improve the course of patients with WM. In the majority of cases, however, complete eradication of the disease does not appear to be possible with ASCT alone. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
36. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft.
- Author
-
Dreger, Peter, Haferlach, Torsten, Eckstein, Volker, Jacobs, Sophia, Suttorp, Meinolf, Löuffler, Helmut, And, Wolfgang Müller-Ruchholtz, and Schmitz, Norbert
- Published
- 1994
- Full Text
- View/download PDF
37. Granulocyte-colony-stimulating factor induces increased serum levels of soluble interleukin 2 receptors preceding engraftment in autologous bone marrow transplantation.
- Author
-
Dreger, Peter, Grelle, Karen, Eckstein, Volker, Suttorp, Meinolf, Müller-Ruchholtz, Wolfgang, Löffler, Helmut, and Schmitz, Norbert
- Published
- 1993
- Full Text
- View/download PDF
38. Precast commercial polyacrylamide gels for separation of DNA amplificates by temperature gradient gel electrophoresis: Application to clonality analysis of lymphomas.
- Author
-
Suttorp, Meinolf, Von Neuhoff, Nils, Tiemann, Markus, Dreger, Peter, Schaub, Jürgen, Löffer, Helmut, Parwaresch, Reza, and Schmitz, Norbert
- Published
- 1996
- Full Text
- View/download PDF
39. Amplification of a Y-chromosomal DNA sequence by the polymerase chain reaction for documentation of residual recipient cells in small samples from bone marrow, peripheral blood and cerebrospinal fluid after bone marrow transplantation.
- Author
-
Suttorp, Meinolf, Sprenger, Christine, Dreger, Peter, Sievers, Erika, Claviez, Alexander, Löffler, Helmut, Schaub, Jürgen, and Schmitz, Norbert
- Published
- 1993
- Full Text
- View/download PDF
40. Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular iymphoma.
- Author
-
Sureda, Anna, Montoto, Silvia, Dreger, Peter, Hamadani, Mehdi, and Pasquini, Marcelo C.
- Subjects
HEMATOPOIETIC stem cell transplantation ,LYMPHOMA treatment ,IMMUNOSUPPRESSION ,LYMPHOMAS ,UNCERTAINTY - Published
- 2018
- Full Text
- View/download PDF
41. Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation.
- Author
-
Rovó A, Kulasekararaj A, Medinger M, Chevallier P, Ribera JM, Peffault de Latour R, Knol C, Iacobelli S, Kanfer E, Bruno B, Maury S, Quarello P, Koh MBC, Schouten H, Blau IW, Tichelli A, Hill A, Risitano A, Passweg J, Marsh J, Dreger P, and Dufour C
- Subjects
- Adolescent, Adult, Aged, Bone Marrow Transplantation, Child, Europe epidemiology, Female, Humans, Male, Middle Aged, Societies, Medical, Anemia, Aplastic blood, Anemia, Aplastic mortality, Anemia, Aplastic therapy, Lymphoma blood, Lymphoma mortality, Lymphoma therapy
- Published
- 2019
- Full Text
- View/download PDF
42. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
- Author
-
Avivi I, Arcaini L, Ferretti VV, Boumendil A, Finel H, Milone G, Zaja F, Liliana D, Musso M, Didier B, Bachy E, Wattad M, Nicolas-Virelizier E, Gramatzki M, Bourhis JH, Caillot D, Haenel A, Held G, Thieblemont C, Jindra P, Pohlreich D, Guilhot F, Kroschinsky F, Wahlin B, Scheid C, Ifrah N, Berthou C, Dreger P, Montoto S, and Conconi A
- Subjects
- Adult, Female, Follow-Up Studies, Humans, Lymphoma, B-Cell, Marginal Zone diagnosis, Male, Middle Aged, Prognosis, Retrospective Studies, Survival Analysis, Transplantation, Autologous, Treatment Failure, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hematopoietic Stem Cell Transplantation methods, Lymphoma, B-Cell, Marginal Zone therapy
- Abstract
The role of autologous stem cell transplantation (ASCT) in patients with marginal zone lymphoma (MZL) is debatable. This study investigated the outcome and prognostic factors affecting the outcome of patients undergoing ASCT for MZL. Eligible patients had non-transformed nodal, extra-nodal (MALT) or splenic MZL (SMZL), aged ≥18 years, who underwent a first ASCT between1994 and 2013 and were reported to the European Society for Blood and Marrow Transplantation, Fondazione Italiana Linfomi or Gruppo Italiano Trapianto Di Midollo Osseo registries. The study included 199 patients, [111 MALT lymphoma, 55 nodal MZL (NMZL) and 33 SMZL]. Median age at transplantation was 56 years. The median number of prior therapies was 2 (range 1-8), including rituximab in 71%. 95% had chemosensitive disease. 89% received a chemotherapy-based high-dose regimen. There were no significant differences in patient and transplant characteristics between the 3 histological subtypes except for a lower percentage of patients previously treated with rituximab in the MALT sub-group and more transplants performed in recent years in the other sub-groups. After a median follow-up of 5 years, 5-year cumulative incidence of relapse/progression and non-relapse mortality were 38% and 9%, respectively. Five-year event-free survival (EFS) and overall survival (OS) were 53% and 73%, respectively. Five-year cumulative incidence of second malignancies was 6%. Multivariate analysis revealed age ≥65 years was associated with a shorter EFS and OS. In addition, patients with SMZL had a shorter OS than those with MALT. ASCT may provide clinical benefit in MZL patients who have failed multiple lines of chemoimmunotherapy., (© 2018 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
43. Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study.
- Author
-
de Wreede LC, Watson M, van Os M, Milligan D, van Gelder M, Michallet M, Dreger P, Dearden CE, Homewood J, Dupuis J, Leporrier M, Karas M, Corront B, Baerlocher GM, Herr W, Choquet S, Niederwieser DW, Sutton L, Kröger N, de Witte TM, and Schetelig On Behalf Of The Chronic Malignancies Working Party Of The Ebmt And The Uk Medical Research Council J
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Male, Middle Aged, Recurrence, Surveys and Questionnaires, Transplantation Conditioning, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation, Leukemia, Lymphocytic, Chronic, B-Cell psychology, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Quality of Life
- Abstract
In chronic lymphocytic leukemia (CLL) medical progress is driven by clinical studies with relapse-free survival (RFS) as the primary endpoint. The randomized EBMT-Intergroup trial compared high-dose therapy and autologous stem cell transplantation (ASCT) to observation and demonstrated a substantial improvement of RFS without showing improved overall survival for the transplant arm. Here we report quality of life (QoL) information of the first 3 years following randomization from that study. The main objective was to assess the impact of treatment on QoL over time. Two secondary analyses were performed to further investigate the impact of ASCT and relapse on QoL. In the primary analysis, we demonstrate an adverse impact of ASCT on QoL which was largest at 4 months and continued throughout the first year after randomization. Further, we demonstrated a sustained adverse impact of relapse on QoL which worsened over time. Despite better disease control by ASCT the side effects thus turned the net effect towards inferior QoL in the first year and comparable QoL in the following 2 years after randomization. This study emphasizes the importance of information concerning QoL impacts when patients are counseled about treatments aimed at improving RFS in the absence of a survival benefit., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.